Cannabinoid Hyperemesis Syndrome Drives Higher Healthcare Costs
Patients with cannabinoid hyperemesis syndrome consumed notably more healthcare resources than non-cannabis users, though the differences were not statistically significant across all cost categories in this small study.
Quick Facts
What This Study Found
Comparing patients with CHS to those who denied cannabis use, researchers found that CHS patients underwent extensive and repeated evaluations across clinic, emergency department, and inpatient settings, consuming more healthcare dollars overall.
Key Numbers
Cost differences between CHS and non-CHS groups were noted but not statistically significant across all categories; CHS patients had repeated evaluations in clinic, ED, and inpatient settings.
How They Did This
Retrospective comparison of costs incurred by patients with CHS versus patients without cannabis use across various healthcare settings.
Why This Research Matters
As cannabis legalization spreads and CHS incidence is expected to rise, early recognition through thorough history-taking could prevent unnecessary workups and reduce the financial burden on both patients and the healthcare system.
The Bigger Picture
The difficulty in diagnosing CHS, which mimics other conditions causing cyclical vomiting, means patients often undergo expensive testing before receiving the correct diagnosis, pointing to a need for better clinical awareness.
What This Study Doesn't Tell Us
Small sample size limited statistical power; cost differences were not consistently significant; single-center study; retrospective design.
Questions This Raises
- ?Would standardized CHS screening protocols in emergency departments reduce unnecessary testing?
- ?How much could early diagnosis save per patient?
Trust & Context
- Key Stat:
- CHS patients undergo extensive repeated evaluations before receiving correct diagnosis
- Evidence Grade:
- Small retrospective comparison without consistently significant cost differences, providing preliminary evidence only.
- Study Age:
- Published in 2021.
- Original Title:
- Prevalence of cannabinoid hyperemesis syndrome and its financial burden on the health care industry.
- Published In:
- Proceedings (Baylor University. Medical Center), 34(6), 654-657 (2021)
- Authors:
- Sandhu, Gurkaminder, Smith, Steven, Stephenson, Kristen, Jaeger, Victoria, John, Rebekah, Shaver, Courtney, Johnson, Christopher
- Database ID:
- RTHC-03493
Evidence Hierarchy
Looks back at existing records to find patterns.
What do these levels mean? →Frequently Asked Questions
What is cannabinoid hyperemesis syndrome?
CHS is a condition caused by long-term cannabis use that produces severe cyclical nausea, vomiting, and abdominal pain. Symptoms resolve with cessation of cannabis use.
Why does CHS lead to high healthcare costs?
Because CHS mimics other conditions, patients often undergo repeated and extensive evaluations in emergency departments and hospitals before receiving the correct diagnosis.
Read More on RethinkTHC
- cannabis-dependence-physical-psychological-addiction-science
- cannabis-perception-vs-evidence-gap
- cannabis-use-disorder-test
- cross-addiction-quit-weed-start-drinking
- is-weed-addictive
- is-weed-addictive-science
- quitting-weed-and-alcohol
- rehab-for-weed-addiction-necessary
- signs-of-cannabis-use-disorder
- weed-vape-pen-addiction
Cite This Study
https://rethinkthc.com/research/RTHC-03493APA
Sandhu, Gurkaminder; Smith, Steven; Stephenson, Kristen; Jaeger, Victoria; John, Rebekah; Shaver, Courtney; Johnson, Christopher. (2021). Prevalence of cannabinoid hyperemesis syndrome and its financial burden on the health care industry.. Proceedings (Baylor University. Medical Center), 34(6), 654-657. https://doi.org/10.1080/08998280.2021.1937874
MLA
Sandhu, Gurkaminder, et al. "Prevalence of cannabinoid hyperemesis syndrome and its financial burden on the health care industry.." Proceedings (Baylor University. Medical Center), 2021. https://doi.org/10.1080/08998280.2021.1937874
RethinkTHC
RethinkTHC Research Database. "Prevalence of cannabinoid hyperemesis syndrome and its finan..." RTHC-03493. Retrieved from https://rethinkthc.com/research/sandhu-2021-prevalence-of-cannabinoid-hyperemesis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.